Trial Profile
A Phase 2 Study of BAY 43-9006 (IND 69896) [sorafenib] in Chemosensitive Relapsed Aggressive Non-Hodgkin's Lymphomas
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 13 Feb 2013
Price :
$35
*
At a glance
- Drugs Sorafenib (Primary)
- Indications Non-Hodgkin's lymphoma
- Focus Biomarker; Therapeutic Use
- 04 Jan 2008 Status change from recruiting to completed.
- 19 Nov 2006 New trial record.